UNS 0.00% 0.5¢ unilife corporation

This article talks about negotiations involving pricing. Detail...

  1. 2,836 Posts.
    lightbulb Created with Sketch. 452
    This article talks about negotiations involving pricing.
    Detail include
    Refunds for heart attacks occurring whilst on drug.
    Pricing reflecting the effectiveness of the drug.

    To achieve these parameters detailed knowledge of patients compliance with injecting the prescribed drug.
    It can be seen that only devises that can record and transmit injecting compliance will achieve these aims.
    In addition we have learned this week that drug manufacturers take out insurance to cover risk associated with the new drug and so one would expect the more evidence to prove the drugs effectiveness would lower premiums.
    Unilife's competitors lack the ability to perform all functions needed to meet these requirements or they are performing in a different market eg diabetics- which is more about balancing BGL .
    Unilife has previously stated that the drug company (Sanofi) will buy the injector for around $200 for each patient. This may equate to a $20 royalty fee each if they are manufactured by Flextronics.
    Unilife may learn its fate by the 29 th.
    All IMO
    http://www.reuters.com/article/heart-amgen-pricing-idUSL2N1GU23H
 
watchlist Created with Sketch. Add UNS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.